Perioperative management of lung cancer patients with cardiovascular complications

Hirotsugu Notsuda, Yasushi Hoshikawa, Akira Sakurada, Chiaki Endo, Sumiko Maeda, Tatsuaki Watanabe, Hiromichi Niikawa, Yasushi Matsuda, Masafumi Noda, Yoshinori Okada, Takashi Kondo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Lung cancer patients with cardiovascular complications often require antithrombotic therapy. In this study, we discuss the present conditions and future problems associated with the perioperative management of such patients. We examined 36 lung cancer patients undergoing surgery who received antithrombotic therapy for cardiovascular complications. Twenty-one patients were administered unfractionated heparin in the perioperative period (heparin group). Fifteen patients were not administered unfractionated heparin in the perioperative period (no-heparin group). No significant intergroup differences were observed in operating time, intraoperative blood loss, duration of chest tube placement, and the number of hospitalization days. However, 2 serious cases of thromboembolism developed after surgery. One was a case of pulmonary thromboembolism and the other was one of superior mesenteric artery thromboembolism. These results suggest that the appropriate perioperative usage of heparin enables the standard surgical treatment of lung cancer patients with cardiovascular complications. We recommend the use of low-molecular-weight heparin or low-dose unfractionated heparin as the antithrombotic agent after lung cancer surgery.

Original languageEnglish
Pages (from-to)255-259
Number of pages5
JournalKyobu geka. The Japanese journal of thoracic surgery
Volume68
Issue number4
Publication statusPublished - 01-04-2015

Fingerprint

Heparin
Lung Neoplasms
Perioperative Period
Thromboembolism
Chest Tubes
Superior Mesenteric Artery
Fibrinolytic Agents
Low Molecular Weight Heparin
Pulmonary Embolism
Hospitalization
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Notsuda, H., Hoshikawa, Y., Sakurada, A., Endo, C., Maeda, S., Watanabe, T., ... Kondo, T. (2015). Perioperative management of lung cancer patients with cardiovascular complications. Kyobu geka. The Japanese journal of thoracic surgery, 68(4), 255-259.
Notsuda, Hirotsugu ; Hoshikawa, Yasushi ; Sakurada, Akira ; Endo, Chiaki ; Maeda, Sumiko ; Watanabe, Tatsuaki ; Niikawa, Hiromichi ; Matsuda, Yasushi ; Noda, Masafumi ; Okada, Yoshinori ; Kondo, Takashi. / Perioperative management of lung cancer patients with cardiovascular complications. In: Kyobu geka. The Japanese journal of thoracic surgery. 2015 ; Vol. 68, No. 4. pp. 255-259.
@article{0cf7c3f5631546869caab4aec3f3b298,
title = "Perioperative management of lung cancer patients with cardiovascular complications",
abstract = "Lung cancer patients with cardiovascular complications often require antithrombotic therapy. In this study, we discuss the present conditions and future problems associated with the perioperative management of such patients. We examined 36 lung cancer patients undergoing surgery who received antithrombotic therapy for cardiovascular complications. Twenty-one patients were administered unfractionated heparin in the perioperative period (heparin group). Fifteen patients were not administered unfractionated heparin in the perioperative period (no-heparin group). No significant intergroup differences were observed in operating time, intraoperative blood loss, duration of chest tube placement, and the number of hospitalization days. However, 2 serious cases of thromboembolism developed after surgery. One was a case of pulmonary thromboembolism and the other was one of superior mesenteric artery thromboembolism. These results suggest that the appropriate perioperative usage of heparin enables the standard surgical treatment of lung cancer patients with cardiovascular complications. We recommend the use of low-molecular-weight heparin or low-dose unfractionated heparin as the antithrombotic agent after lung cancer surgery.",
author = "Hirotsugu Notsuda and Yasushi Hoshikawa and Akira Sakurada and Chiaki Endo and Sumiko Maeda and Tatsuaki Watanabe and Hiromichi Niikawa and Yasushi Matsuda and Masafumi Noda and Yoshinori Okada and Takashi Kondo",
year = "2015",
month = "4",
day = "1",
language = "English",
volume = "68",
pages = "255--259",
journal = "Japanese Journal of Thoracic Surgery",
issn = "0021-5252",
publisher = "Nankodo Co., Ltd.",
number = "4",

}

Notsuda, H, Hoshikawa, Y, Sakurada, A, Endo, C, Maeda, S, Watanabe, T, Niikawa, H, Matsuda, Y, Noda, M, Okada, Y & Kondo, T 2015, 'Perioperative management of lung cancer patients with cardiovascular complications', Kyobu geka. The Japanese journal of thoracic surgery, vol. 68, no. 4, pp. 255-259.

Perioperative management of lung cancer patients with cardiovascular complications. / Notsuda, Hirotsugu; Hoshikawa, Yasushi; Sakurada, Akira; Endo, Chiaki; Maeda, Sumiko; Watanabe, Tatsuaki; Niikawa, Hiromichi; Matsuda, Yasushi; Noda, Masafumi; Okada, Yoshinori; Kondo, Takashi.

In: Kyobu geka. The Japanese journal of thoracic surgery, Vol. 68, No. 4, 01.04.2015, p. 255-259.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Perioperative management of lung cancer patients with cardiovascular complications

AU - Notsuda, Hirotsugu

AU - Hoshikawa, Yasushi

AU - Sakurada, Akira

AU - Endo, Chiaki

AU - Maeda, Sumiko

AU - Watanabe, Tatsuaki

AU - Niikawa, Hiromichi

AU - Matsuda, Yasushi

AU - Noda, Masafumi

AU - Okada, Yoshinori

AU - Kondo, Takashi

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Lung cancer patients with cardiovascular complications often require antithrombotic therapy. In this study, we discuss the present conditions and future problems associated with the perioperative management of such patients. We examined 36 lung cancer patients undergoing surgery who received antithrombotic therapy for cardiovascular complications. Twenty-one patients were administered unfractionated heparin in the perioperative period (heparin group). Fifteen patients were not administered unfractionated heparin in the perioperative period (no-heparin group). No significant intergroup differences were observed in operating time, intraoperative blood loss, duration of chest tube placement, and the number of hospitalization days. However, 2 serious cases of thromboembolism developed after surgery. One was a case of pulmonary thromboembolism and the other was one of superior mesenteric artery thromboembolism. These results suggest that the appropriate perioperative usage of heparin enables the standard surgical treatment of lung cancer patients with cardiovascular complications. We recommend the use of low-molecular-weight heparin or low-dose unfractionated heparin as the antithrombotic agent after lung cancer surgery.

AB - Lung cancer patients with cardiovascular complications often require antithrombotic therapy. In this study, we discuss the present conditions and future problems associated with the perioperative management of such patients. We examined 36 lung cancer patients undergoing surgery who received antithrombotic therapy for cardiovascular complications. Twenty-one patients were administered unfractionated heparin in the perioperative period (heparin group). Fifteen patients were not administered unfractionated heparin in the perioperative period (no-heparin group). No significant intergroup differences were observed in operating time, intraoperative blood loss, duration of chest tube placement, and the number of hospitalization days. However, 2 serious cases of thromboembolism developed after surgery. One was a case of pulmonary thromboembolism and the other was one of superior mesenteric artery thromboembolism. These results suggest that the appropriate perioperative usage of heparin enables the standard surgical treatment of lung cancer patients with cardiovascular complications. We recommend the use of low-molecular-weight heparin or low-dose unfractionated heparin as the antithrombotic agent after lung cancer surgery.

UR - http://www.scopus.com/inward/record.url?scp=84941733383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941733383&partnerID=8YFLogxK

M3 - Article

VL - 68

SP - 255

EP - 259

JO - Japanese Journal of Thoracic Surgery

JF - Japanese Journal of Thoracic Surgery

SN - 0021-5252

IS - 4

ER -